Thursday, 9 Oct 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    Nobel Prize 2025 in Medicine: Three Scientists Who Changed the Future of Immunology
    Nobel Prize 2025 in Medicine: Three Scientists Who Changed the Future of Immunology
    08/10/2025
    नोबेल पुरस्कार 2025 – मेडिसिन कैटेगरी में तीन वैज्ञानिकों की शानदार जीत!
    नोबेल पुरस्कार 2025 – मेडिसिन कैटेगरी में तीन वैज्ञानिकों की शानदार जीत!
    08/10/2025
    Comviva Fintech Platforms Hits  Billion Daily Transaction Milestone, Strengthening its Global Fintech Dominance
    Comviva Fintech Platforms Hits $1 Billion Daily Transaction Milestone, Strengthening its Global Fintech Dominance
    08/10/2025
    Financing Asia’s Future: IJGlobal’s Infrastructure Finance Forum (IFF): Asia 2025 comes to Singapore
    Financing Asia’s Future: IJGlobal’s Infrastructure Finance Forum (IFF): Asia 2025 comes to Singapore
    08/10/2025
    Newmark Acquires Leading Real Estate Consulting and Managed Services Firm, RealFoundations
    Newmark Acquires Leading Real Estate Consulting and Managed Services Firm, RealFoundations
    08/10/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • global
  • Business
  • june
  • announced
  • today
  •  and
  • july
  •  the
  • company
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Travel

Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment

PRNW Agency
Last updated: 26/08/2025 2:31 PM
PRNW Agency
Share
6 Min Read
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
SHARE
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
  • Abbott’s denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for millions of Thais
  • This approval builds on Abbott’s biosimilar portfolio in Asia Pacific, following recent launches in Malaysia and India

BANGKOK, Aug. 26, 2025 /PRNewswire/ — Abbott (NYSE: ABT), the global healthcare leader, has received regulatory approval for the first denosumab biosimilar in Thailand, expanding access to advanced therapies for osteoporosis and cancer-related bone loss. With the introduction of Abbott’s denosumab biosimilar in Thailand, this advanced biologic treatment will be more affordable and accessible for the estimated 3 million people suffering from osteoporosis and bone-disease related illness in the country.1,2,3 

- Advertisement -

“For people living with osteoporosis or cancer-related bone disease, access to a denosumab biologic can be truly life-changing,” said Karim Elmashad, divisional vice president of Abbott’s medicines business in Asia Pacific. “With this approval, people in Thailand affected by these conditions now have greater access to this transformative therapy.”

- Advertisement -

Addressing a growing health challenge
Osteoporosis, a chronic and age-related disease, is a serious public health concern.4,5 The condition has a significant and often debilitating impact, including fractures that lead to loss of independence and reduced quality of life.6 In Thailand, 1 in 5 women and 1 in 10 men have osteoporosis, with prevalence increasing significantly with age.7 As the country’s population ages — projected to reach 25% aged 60 or older within the next decade — the burden of osteoporosis-related fractures, disability, and healthcare costs is expected to rise sharply.7,8 

- Advertisement -

Fractures caused by osteoporosis can lead to loss of independence, and reduced quality of life. Yet fewer than 40% of hip fracture patients in Thailand begin anti-osteoporosis therapy, often due to barriers such as cost, awareness, and treatment availability.7,9,10

- Advertisement -

Abbott will provide denosumab as part of its broader strategy to expand access to high-quality medicines across key therapeutic areas including oncology, immunology and women’s health through strategic partnerships with biotechnology companies.

- Advertisement -

With a 135-year history of delivering life-changing healthcare solutions, Abbott remains committed to helping people live their best at every stage of their lives. Building on its well-established biosimilars portfolio in Latin America and India, and following a recent biosimilar launch in Malaysia, Abbott is accelerating its expansion in the Asia-Pacific region. The introduction of denosumab in Thailand marks a significant step in addressing the region’s growing burden of chronic diseases, while expanding access to a high-quality treatment at a more accessible price.

- Advertisement -

For more info on Abbott biosimilars, please visit www.medicines.abbott

- Advertisement -

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

- Advertisement -

Connect with us at Abbott and on LinkedIn, Facebook, Instagram, X and YouTube.

- Advertisement -

References

- Advertisement -
  1. Vázquez-Sánchez R, Navarro-Dávila M, Herráiz ER, et al. Biosimilars and access to biologic therapy in immune-mediated diseases. Expert Opin Biol Ther. 2024;24(7):647-653. doi:10.1080/14712598.2024.2350440
  2. Morin S, Segafredo G, Piccolis M, et al. Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities. Lancet Glob Health. 2023;11(1):e145-e154. doi:10.1016/S2214-109X(22)00460-0
  3. Chen HH, Yemeke T, Ozawa S. Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19. PLoS One. 2024;19(6):e0304851. doi:10.1371/journal.pone.0304851
  4. Phanphaisarn A, Patumanond J, Settakorn J, Chaiyawat P, Klangjorhor J, Pruksakorn D. Prevalence and Survival Patterns of Patients with Bone Metastasis from Common Cancers in Thailand. Asian Pac J Cancer Prev. 2016;17(9):4335-4340.
  5. Asavamongkolkul A, Adulkasem N, Chotiyarnwong P, et al. Prevalence of osteoporosis, sarcopenia, and high falls risk in healthy community-dwelling Thai older adults: a nationwide cross-sectional study [published correction appears in JBMR Plus. 2024 Mar 22;8(4):ziae040. doi: 10.1093/jbmrpl/ziae040.]. JBMR Plus. 2024;8(2):ziad020. doi:10.1093/jbmrpl/ziad020
  6. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician’s guide to prevention and treatment of osteoporosis [published correction appears in Osteoporos Int. 2022 Oct;33(10):2243. doi: 10.1007/s00198-022-06479-8.]. Osteoporos Int. 2022;33(10):2049-2102. doi:10.1007/s00198-021-05900-y
  7. Charoenngam N, Pongchaiyakul C. Current issues in evaluation and management of osteoporosis in Thailand. Osteoporos Sarcopenia. 2023;9(2):53-59. doi:10.1016/j.afos.2023.05.002
  8. Statista. Share of total population older than 60 years old in Thailand between 2022 and 2023, with a forecast to 2040. https://www.statista.com/statistics/713667/thailand-forecast-aging-population/ Accessed July 3, 2025.
  9. Mahaisavariya C, Vanitcharoenkul E, Kitcharanant N, Chotiyarnwong P, Unnanuntana A. Exploring the osteoporosis treatment gap after fragility hip fracture at a Tertiary University Medical Center in Thailand. BMC Geriatr. 2023;23(1):70. doi:10.1186/s12877-023-03778-5
  10. Chanidkul P, Sribenjalak D, Charoenngam N, Pongchaiyakul C. The proportion of Thai postmenopausal women who would be eligible for anti-osteoporosis therapy. PLoS One. 2023;18(2):e0279829. doi:10.1371/journal.pone.0279829

 

- Advertisement -
Maximus Ranks No. 27 on the 2025 Inc. 5000 List of Americas Fastest-Growing Private Companies
New Bounteous White Paper Maps the AI Whitespace for Business Leaders
Omdia Forecasts Large-Area Display Shipments to Grow 2.8% YoY in 2025, Mobile PC Displays Lead the Growth
CGTMSE’s Silver Jubilee Celebration – Felicitation of Member Lending Institutions
Sufi Star Heer Walia Casts a Spell Over Delhi at Bonne Foi 65
TAGGED: for theabbottabbottsabtaccessadvancedapprovalaugbangkokbiologicbiosimilarbonecancerrelateddenosumabdiseaseexpandingfirstfirst denosumabfracturesglobalHealthhealthcareintroductionleaderlossnewsnyseosteoporosispeoplereceivedreceivesregulatorythailandtherapiestreatment
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
Health

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer

21/07/2025
Bybit Upgrades Convert Features with Exclusive Lucky Draw
Business

Bybit Upgrades Convert Features with Exclusive Lucky Draw

05/10/2025
ANRO Deadline: Rosen Law Firm Urges Alto Neuroscience, Inc. (NYSE: ANRO) Stockholders to Contact the Firm for Information About Their Rights
Business

ANRO Deadline: Rosen Law Firm Urges Alto Neuroscience, Inc. (NYSE: ANRO) Stockholders to Contact the Firm for Information About Their Rights

14/09/2025
SBI Life Insurance registers New Business Premium of Rs. 7,268 crores for the period ended on 30th June, 2025
News

SBI Life Insurance registers New Business Premium of Rs. 7,268 crores for the period ended on 30th June, 2025

26/07/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?